世界の肝性脳症治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV01124)
◆英語タイトル:Global Hepatic Encephalopathy Drug Market Insights and Forecast to 2026
◆商品コード:QYR20NV01124
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:111
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは肝性脳症治療薬の世界市場について調査・分析した資料です。種類別(RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他)の市場規模、用途別(クリニック、病院、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別肝性脳症治療薬の競争状況、市場シェア
・世界の肝性脳症治療薬市場:種類別市場規模 2015年-2020年(RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他)
・世界の肝性脳症治療薬市場:種類別市場規模予測 2021年-2026年(RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他)
・世界の肝性脳症治療薬市場:用途別市場規模 2015年-2020年(クリニック、病院、その他)
・世界の肝性脳症治療薬市場:用途別市場規模予測 2021年-2026年(クリニック、病院、その他)
・北米の肝性脳症治療薬市場分析:米国、カナダ
・ヨーロッパの肝性脳症治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの肝性脳症治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の肝性脳症治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの肝性脳症治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Hepatic Encephalopathy Drug Market
The global Hepatic Encephalopathy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Hepatic Encephalopathy Drug Scope and Market Size
Hepatic Encephalopathy Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatic Encephalopathy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Hepatic Encephalopathy Drug market is segmented into
RBX-2660
KLS-13019
GR-3027
SYNB-1020
Others

Segment by Application, the Hepatic Encephalopathy Drug market is segmented into
Clinic
Hospital
Others

Regional and Country-level Analysis
The Hepatic Encephalopathy Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hepatic Encephalopathy Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hepatic Encephalopathy Drug Market Share Analysis
Hepatic Encephalopathy Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hepatic Encephalopathy Drug business, the date to enter into the Hepatic Encephalopathy Drug market, Hepatic Encephalopathy Drug product introduction, recent developments, etc.

The major vendors covered:
Alfa Wassermann S.p.A
Cosmo Pharmaceuticals S.p.A
Horizon Pharma Plc
KannaLife Sciences, Inc.
Ocera Therapeutics, Inc.
Rebiotix Inc.
Spherium Biomed S.L.
Umecrine Cognition AB

【レポートの目次】

1 Study Coverage
1.1 Hepatic Encephalopathy Drug Product Introduction
1.2 Market Segments
1.3 Key Hepatic Encephalopathy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type
1.4.2 RBX-2660
1.4.3 KLS-13019
1.4.4 GR-3027
1.4.5 SYNB-1020
1.4.6 Others
1.5 Market by Application
1.5.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Hepatic Encephalopathy Drug Market Size, Estimates and Forecasts
2.1.1 Global Hepatic Encephalopathy Drug Revenue 2015-2026
2.1.2 Global Hepatic Encephalopathy Drug Sales 2015-2026
2.2 Global Hepatic Encephalopathy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Hepatic Encephalopathy Drug Competitor Landscape by Players
3.1 Hepatic Encephalopathy Drug Sales by Manufacturers
3.1.1 Hepatic Encephalopathy Drug Sales by Manufacturers (2015-2020)
3.1.2 Hepatic Encephalopathy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hepatic Encephalopathy Drug Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hepatic Encephalopathy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drug Revenue in 2019
3.2.5 Global Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hepatic Encephalopathy Drug Price by Manufacturers
3.4 Hepatic Encephalopathy Drug Manufacturing Base Distribution, Product Types
3.4.1 Hepatic Encephalopathy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatic Encephalopathy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hepatic Encephalopathy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Hepatic Encephalopathy Drug Market Size by Type (2015-2020)
4.1.1 Global Hepatic Encephalopathy Drug Sales by Type (2015-2020)
4.1.2 Global Hepatic Encephalopathy Drug Revenue by Type (2015-2020)
4.1.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hepatic Encephalopathy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hepatic Encephalopathy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Hepatic Encephalopathy Drug Market Size by Application (2015-2020)
5.1.1 Global Hepatic Encephalopathy Drug Sales by Application (2015-2020)
5.1.2 Global Hepatic Encephalopathy Drug Revenue by Application (2015-2020)
5.1.3 Hepatic Encephalopathy Drug Price by Application (2015-2020)
5.2 Hepatic Encephalopathy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatic Encephalopathy Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Hepatic Encephalopathy Drug by Country
6.1.1 North America Hepatic Encephalopathy Drug Sales by Country
6.1.2 North America Hepatic Encephalopathy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hepatic Encephalopathy Drug Market Facts & Figures by Type
6.3 North America Hepatic Encephalopathy Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Hepatic Encephalopathy Drug by Country
7.1.1 Europe Hepatic Encephalopathy Drug Sales by Country
7.1.2 Europe Hepatic Encephalopathy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Type
7.3 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Hepatic Encephalopathy Drug by Region
8.1.1 Asia Pacific Hepatic Encephalopathy Drug Sales by Region
8.1.2 Asia Pacific Hepatic Encephalopathy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Type
8.3 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Hepatic Encephalopathy Drug by Country
9.1.1 Latin America Hepatic Encephalopathy Drug Sales by Country
9.1.2 Latin America Hepatic Encephalopathy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Type
9.3 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Hepatic Encephalopathy Drug by Country
10.1.1 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country
10.1.2 Middle East and Africa Hepatic Encephalopathy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments
11.2 Cosmo Pharmaceuticals S.p.A
11.2.1 Cosmo Pharmaceuticals S.p.A Corporation Information
11.2.2 Cosmo Pharmaceuticals S.p.A Description and Business Overview
11.2.3 Cosmo Pharmaceuticals S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Products Offered
11.2.5 Cosmo Pharmaceuticals S.p.A Related Developments
11.3 Horizon Pharma Plc
11.3.1 Horizon Pharma Plc Corporation Information
11.3.2 Horizon Pharma Plc Description and Business Overview
11.3.3 Horizon Pharma Plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Products Offered
11.3.5 Horizon Pharma Plc Related Developments
11.4 KannaLife Sciences, Inc.
11.4.1 KannaLife Sciences, Inc. Corporation Information
11.4.2 KannaLife Sciences, Inc. Description and Business Overview
11.4.3 KannaLife Sciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Products Offered
11.4.5 KannaLife Sciences, Inc. Related Developments
11.5 Ocera Therapeutics, Inc.
11.5.1 Ocera Therapeutics, Inc. Corporation Information
11.5.2 Ocera Therapeutics, Inc. Description and Business Overview
11.5.3 Ocera Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Products Offered
11.5.5 Ocera Therapeutics, Inc. Related Developments
11.6 Rebiotix Inc.
11.6.1 Rebiotix Inc. Corporation Information
11.6.2 Rebiotix Inc. Description and Business Overview
11.6.3 Rebiotix Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Rebiotix Inc. Hepatic Encephalopathy Drug Products Offered
11.6.5 Rebiotix Inc. Related Developments
11.7 Spherium Biomed S.L.
11.7.1 Spherium Biomed S.L. Corporation Information
11.7.2 Spherium Biomed S.L. Description and Business Overview
11.7.3 Spherium Biomed S.L. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Products Offered
11.7.5 Spherium Biomed S.L. Related Developments
11.8 Umecrine Cognition AB
11.8.1 Umecrine Cognition AB Corporation Information
11.8.2 Umecrine Cognition AB Description and Business Overview
11.8.3 Umecrine Cognition AB Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Products Offered
11.8.5 Umecrine Cognition AB Related Developments
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hepatic Encephalopathy Drug Market Estimates and Projections by Region
12.1.1 Global Hepatic Encephalopathy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.2.2 North America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hepatic Encephalopathy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hepatic Encephalopathy Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatic Encephalopathy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の肝性脳症治療薬市場2026:インサイト・予測(Global Hepatic Encephalopathy Drug Market Insights and Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。